Navigation Links
Organovo Reports Fiscal 2013 Financial Results

SAN DIEGO, May 28, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQX: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, has reported on its financial results for the three month transition period ended March 31, 2013, completing the Company's fiscal 2013 reporting. The Company also reported on its corporate highlights during fiscal 2013.

FY2013 Corporate Highlights

  • Organovo achieved first fully cellular, functional 3D bioprinted liver tissue, demonstrating the power of our bioprinting technology to create functional human tissue that replicates human biology better than what has come before;
  • Reduced derivative-liability-laden warrant overhang by approximately 88 percent, resulting in shareholder equity at the end of FY 2013 exceeding the respective initial listing requirement for either NYSE or NASDAQ;
  • Formed a collaboration with OHSU Knight Cancer Institute to develop more clinically predictive in vitro three dimensional cancer models;
  • Partnered with ZenBio to create 3D tissue models;
  • Formed a partnership with Autodesk Research to develop 3D bioprinting software;
  • Received multiple issued patents, including the Company's first assigned patent, and acquired an additional issued patent;
  • Joined QX tier of the OTC Markets;
  • Moved to a new, larger research and headquarters facility;
  • Expanded executive management team with the addition of Dr. Eric David as Chief Strategic Officer and Michael Renard as Executive Vice President of Commercial Operations;
  • Appointed additional independent director James Glover to the Board of Directors and to serve as Audit Committee Chairman;
  • Featured in Wall Street Journal.
  • "Organovo reached important milestones in demonstrating our ability to create functional human tissues in fiscal year 2013," stated Keith Murphy, chief executive officer of Organovo. "We continue to grow quickly, attract great partners, and see tremendous scientific results from our bioprinting efforts. Building upon our financial and operational achievements during the last year, we look forward to continued success in fiscal 2014 as we seek to continue to provide long-term shareholder value."

    Change in Fiscal Year End On March 31, 2013, the Board of Directors of the Company (the "Board") approved a change in the Company's fiscal year end from December 31st to March 31st. As a result of this change, the Company has filed a Transition Report on Form 10-K for the three-month transition period ended March 31, 2013.

    Financial ResultsComparison of the three months ended March 31, 2013 and 2012RevenuesRevenues of $0.2 million for the three months ended March 31, 2013 increased approximately $0.1 million, or nearly 100%, over revenues of $0.1 million for the same period in 2012. That increase can be attributed to $0.1 million of grant revenue during the three months ended March 31, 2013. The Company had no active grants or grant revenue during the three months ended March 31, 2012.

    Operating ExpensesOperating expenses increased approximately $2.8 million, or 200%, from $1.4 million for the three months ended March 31, 2012 to $4.2 million for the three months ended March 31, 2013. Of this increase, $1.9 million is related to increased selling, general and administrative expense while the other $0.9 million relates to increased investment in research and development expense. These increases are attributed to the continued strategic growth of the Company, including additional staffing to support research and development initiatives, incremental investment associated with strategic growth and commercialization project initiatives, expenses related to operating a publicly traded corporation, relocation to a larger facility, and increased stock compensation expense relative to employees and certain consulting services.

    Research and Development Expenses Research and development expense increased $0.9 million, or 180%, from $0.5 million for the three months ended March 31, 2012 to $1.4 million for the three months ended March 31, 2013 as the Company more than doubled its research staff to support its obligations under certain collaborative research agreements and government grants, and to expand product development efforts in preparation for research-derived revenues. Full-time research and development staffing increased from ten full-time employees as of March 31, 2012 to twenty-one full-time employees as of March 31, 2013. In addition to the incremental payroll, benefits and stock-based compensation resulting from increased staffing levels, the Company relocated its facilities to accommodate its growing research staff, and increased its spending on lab equipment and supplies in proportion to its increased research activities.

    Selling, General and Administrative Expenses Selling, general and administrative expenses increased $1.9 million, or 211%, from $0.9 million for the three months ended March 31, 2012 to $2.8 million for the three months ended March 31, 2013. Increased staffing expenses of approximately $0.6 million included full-time administrative headcount which was increased from five full-time employees to nine full-time employees, including the addition of two executives, to provide strategic infrastructure in developing collaborative relationships and preparation for commercialization of research based product introductions and to address the additional compliance requirements of becoming a publicly traded corporation. In addition, stock-based compensation costs increased due to approximately $0.4 million in additional grants to employees, and approximately $0.3 million for the revaluation of restricted common stock issued to consultants during the three months ended March 31, 2013. Finally, the Company incurred approximately $0.3 million more in external expenses related to becoming a publicly traded corporation, including SEC financial reporting, investor relations, corporate governance, and audit fees.

    Other Income (Expense) The $23.7 million decrease in other expenses as compared to the three months ended March 31, 2012 was primarily due to the inclusion of one-time non-cash transaction costs associated with the Merger and 2012 Private Placements in other expense during the first quarter of 2012, including approximately $19.0 million of expense for the excess of the fair value of warrant liabilities over proceeds received, $2.1 million of financing costs in excess of proceeds received and $1.0 million in interest expense from the accretion of debt discount and amortization of deferred financing costs related to the 2011 Private Placement, the Merger and the 2012 Private Placement. The non-cash expense related to the change in fair value of warrant liabilities decreased by approximately $1.5 million, due in part to fewer warrants outstanding as of March 31, 2013. Interest expense of less than $0.1 million for the three months ended March 31, 2013 is primarily related to the modification of certain warrant agreements during the period.

    Various factors are considered in the pricing models we use to value the warrants, including the Company's current stock price, the remaining life of the warrants, the volatility of the Company's stock price, and the risk free interest rate. Future changes in these factors will have a significant impact on the computed fair value of the warrant liability. As such, we expect future changes in the fair value of the warrants to continue to vary significantly from quarter to quarter.

    Financial Condition, Liquidity and Capital Resources Since its inception, the Company has primarily devoted its efforts to research and development, business planning, raising capital, recruiting management and technical staff, and acquiring operating assets. Accordingly, the Company is considered to be in the development stage.

    Since inception, the Company has incurred negative cash flows from operations. As of March 31, 2013, the Company had cash and cash equivalents of $15.6 million and an accumulated deficit of $66.4 million. The Company also had negative cash flows from operations of $2.8 million for the three months ended March 31, 2013. At March 31, 2013, we had total current assets of $16.1 million and current liabilities of $8.4 million, resulting in working capital of $7.7 million. Net cash used in investing activities was $0.2 million for the three months ended March 31, 2013. The increased use of net cash in investing activities was primarily due to purchases of equipment for the research lab.

    Net cash provided by financing activities was $3.7 million for the three months ended March 31, 2013.

    On February 5, 2013, the Company provided a Notice of Redemption to affected warrant holders, of approximately 2.4 million warrant shares, that they would have until March 14, 2013 to exercise their outstanding warrants at $1.00 per share. Thereafter, any warrants that remained unexercised would have been automatically redeemed by the Company at a redemption price of $0.0001 per share of common stock then issuable upon exercise of the redeemed warrant. As of March 14, 2013, all redeemable warrants had been exercised for net proceeds of approximately $2.3 million. During the three months ended March 31, 2013, the Company also received approximately $1.4 million of additional proceeds from the exercise of other warrants unrelated to the Notice of Redemption.

    Through March 31, 2013, the Company has financed its operations primarily through the sale of convertible notes, the private placement of equity securities, and through revenue derived from grants or collaborative research agreements. Based on its current operating plan and available cash resources, the Company has sufficient resources to fund its business for at least the next twelve months.

    About Organovo Holdings, Inc.
    Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, our technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at

    Safe Harbor Statement
    Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our transition report on Form 10-KT filed with the SEC on May 24, 2013. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.ORGANOVO HOLDINGS, INC. (A development stage company) CONSOLIDATED BALANCE SHEETS
    (in thousands except per share data) 

    March 31,


    December 31,
    December 31,
    AssetsCurrent AssetsCash and cash equivalents$  15,628$
    340Grant receivable101162—Inventory88360292Deferred financing costs——319Prepaid expenses and other current assets32752780Total current assets16,14415,8661,031Fixed Assets — Net1,045714278Restricted Cash8888—Other Assets — Net9881100Total assets$  17,375$
    ,409Liabilities and Stockholders' Equity (Deficit)Current LiabilitiesAccounts payable$
    58Accrued expenses780981438Deferred revenue53—153Capital lease obligation, current portion1010—Accrued interest payable——24Convertible notes payable——704Warrant liabilities, current6,89820,619—Total current liabilities8,38222,0351,977Warrant liabilities, non-current——1,267Deferred revenue, net of current portion9——Capital lease obligation, net of current portion1517—Total liabilities$
    3,244Commitments and Contingencies (see Note 8)Stockholders' Equity (Deficit)Common stock, $0.001 par value; 150,000,000 shares authorized, 64,686,919,

    58,535,411 and 22,445,254 shares issued and outstanding at March 31,

    2013, December 31, 2012 and December 31, 2011, respectively655922Additional paid-in capital75,26944,8834,835Deficit accumulated during the development stage(66,365)(50,245)(6,692)Total stockholders' equity (deficit)8,969(5,303)(1,835)Total Liabilities and Stockholders' Equity (Deficit)$  17,375$
    (A development stage company) CONSOLIDATED STATEMENTS OF OPERATIONS
    (in thousands except per share data)Three Months
    March 31,

    Three Months
    March 31,

    Year Ended
    December 31,

    Year Ended
    December 31,

    Year Ended
    December 31,

    Period from
    April 19, 2007

    March 31, 2013
    224Collaborations981201,035688751,896Grants117—16257528943Total Revenue2151201,1979696033,063Cost of product revenue———121—134Selling, general, and administrative

    expenses2,7929027,0801,73357812,539Research and development
    1,4485473,4361,4201,2038,082Loss from Operations(4,025)(1,329)(9,319)(2,305)(1,178)(17,692)Other Income (Expense)Fair value of warrant

    liabilities in excess of

    proceeds received—(19,019)(19,019)——(19,019)Change in fair value of

    warrant liabilities(12,034)(13,506)(9,931)(7)—(21,972)Financing transaction costs in

    excess of proceeds

    received—(2,130)(2,130)——(2,130)Loss on inducement to

    exercise warrants——(1,904)——(1,904)Loss on disposal of fixed assets——(158)——(158)Interest expense(65)(1,088)(1,088)(2,067)(161)(3,471)Interest income4—5——11Other expense—(9)(9)(4)—(30)Total Other Income (Expense)(12,095)(35,752)(34,234)(2,078)(161)(48,673)Net Loss$
    (66,365)Net loss per common share

    — basic and diluted$
    (0.09)Weighted average number of

    shares used in computing net

    loss per share — basic and diluted61,750,15731,591,66343,149,65722,925,69414,620,140 ORGANOVO HOLDINGS, INC.
    (A development stage company)
    March 31,

    Three Months
    March 31,

    Year Ended
    December 31,

    Year Ended
    December 31,

    Year Ended
    December 31,

    Period from
    April 19, 2007
    March 31, 2013
    Cash Flows From Operating ActivitiesNet loss






    (66,365)Adjustments to reconcile net loss to net cash used in operating activities:Amortization of debt discount




    2,084Loss on disposal of fixed assets


    158Depreciation and amortization






    431Amortization of deferred financing costs




    438Amortization of warrants issued for services



    817Interest accrued on convertible notes payable




    495Warrants issued in connection with exchange agreement


    528Loss on inducement to exercise warrants


    1,904Expense associated with warrant modification


    65Stock-based compensation






    2,300Fair value of warrant liabilities in excess of proceeds



    19,019Change in fair value of warrant liabilities





    21,972Increase (decrease) in cash resulting from changes in:Grants receivable










    (751)Prepaid expenses and other current assets






    (255)Accounts payable






    641Accrued expenses






    780Deferred revenue






    62Accrued interest


    Net cash used in operating activities






    (15,778)Cash Flows From Investing ActivitiesRestricted cash deposits



    (88)Purchases of fixed assets






    (921)Purchases of intangible assets




    (114)Net cash used in investing activities






    (1,123)Cash Flows From Financing ActivitiesProceeds from issuance of convertible notes payable



    4,630Proceeds from issuance of common stock and exercise of warrants, net




    28,438Proceeds from exercise of stock options


    18Proceeds from issuance of related party notes payable



    250Repayment of related party notes payable


    (250)Repayment of convertible notes and interest payable



    (110)Principal payments on capital lease obligations



    (9)Deferred financing costs


    (438)Net cash provided by financing activities






    32,529Net Increase in Cash and Cash Equivalents






    15,628Cash and Cash Equivalents at Beginning of Period






    Cash and Cash Equivalents at End of Period






    4,817Supplemental Disclosures of Cash Flow Information:Interest




    $Income Taxes



    SOURCE Organovo Holdings, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Organovo Holdings Appoints James T. Glover to Board of Directors
    2. Organovo Announces Two Issued Patents, First Company Patent and Key Founder Patent
    3. Organovo, Inc. Investor Presentation Now Available for On-demand Viewing at
    4. Organovo Reports Q2 2012 Financial Results, Provides Business Update
    5. Market Boosted by Strong Tech Earnings: Bank of America Corp., MAP Pharmaceuticals Inc., Swingplane Ventures Inc., World Moto, Inc., Organovo Holdings, Inc.
    6. Organovo and OHSU Knight Cancer Institute Announce Collaboration in Cancer Research
    7. Organovo Holdings, Inc. announces redemption of 2.9 million outstanding warrants
    8. Organovo Reports 2012 Financial Results
    9. Organovo Holdings, Inc. Announces Change of Fiscal Year
    10. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    11. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    Post Your Comments:
    (Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare ... CPR training aide "cprCUBE" on Kickstarter. The device will ... during cardiac arrests with better efficiency compared to the ... offers real-time feedback on efficacy of the compression for ... campaign has a goal to raise $5,000. ...
    (Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
    (Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... October 13, 2017 , ... The International Association ... standards of excellence for the field of eating disorders, announces the opening of ... 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. , ...
    (Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
    (Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
    (Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
    (Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
    Breaking Medicine News(10 mins):